# AZD0585 Phase III Long-term Study in Japan

> **NCT02463071** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 383 (actual)

## Conditions studied

- Hypertriglyceridemia

## Interventions

- **DRUG:** AZD0585
- **DRUG:** AZD0585 placebo

## Key facts

- **NCT ID:** NCT02463071
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-10
- **Primary completion:** 2017-03-11
- **Final completion:** 2017-03-11
- **Target enrollment:** 383 (ACTUAL)
- **Last updated:** 2018-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02463071

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02463071, "AZD0585 Phase III Long-term Study in Japan". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02463071. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*